• Twist Bioscience Corporation (NASDAQ:TWST) reported an EPS of -$0.44, surpassing the estimated EPS of -$0.50.
• The company's revenue for the quarter was approximately $99 million, exceeding the estimated revenue of $97.4 million.
• Twist Bioscience demonstrates strong revenue growth with a price-to-sales ratio of about 4.21.

Twist Bioscience Corporation, listed on NASDAQ:TWST, is a prominent player in the biotech industry, specifically within the biomedical and genetics sector. The company focuses on providing synthetic DNA-based products and services, which are crucial for research and development in various fields, including healthcare and agriculture. Twist Bioscience competes with other biotech firms in the Zacks Medical - Biomedical and Genetics industry.

On November 14, 2025, Twist Bioscience reported its earnings before the market opened. The company posted an earnings per share (EPS) of -$0.44, which was better than the estimated EPS of -$0.50. Despite this improvement, the quarterly loss of $0.44 per share was slightly higher than the Zacks Consensus Estimate of a $0.40 loss, as highlighted by Seeking Alpha. This marks an improvement from the previous year's loss of $0.59 per share.

Twist Bioscience's revenue for the quarter was approximately $99 million, surpassing the estimated revenue of $97.4 million. This revenue also exceeded the Zacks Consensus Estimate by 1.69% and marked a significant increase from the $84.71 million reported in the same quarter last year. Over the past four quarters, Twist Bioscience has consistently surpassed consensus revenue estimates, achieving this feat four times.

Twist Bioscience continues to demonstrate strong revenue growth. The company's price-to-earnings (P/E) ratio is approximately -20.42, indicating negative earnings. However, the price-to-sales ratio of about 4.21 suggests that investors are willing to pay $4.21 for every dollar of sales, reflecting confidence in the company's revenue potential.

Twist Bioscience maintains a relatively low level of debt, with a debt-to-equity ratio of about 0.16. The current ratio of approximately 3.64 indicates a strong ability to cover short-term liabilities with short-term assets. Despite challenges, the company remains focused on its strategic direction and potential growth areas, as discussed in its Q4 2025 earnings call.